Skip to main
NXTC
NXTC logo

Nextcure (NXTC) Stock Forecast & Price Target

Nextcure (NXTC) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 64%
Buy 18%
Hold 9%
Sell 9%
Strong Sell 0%

Bulls say

NextCure Inc. shows a promising financial outlook based on its innovative immunomedicine pipeline, particularly the potential of LNCB74, which has demonstrated superior efficacy in preclinical trials compared to similar constructs, thereby positioning the company favorably within a competitive landscape. Additionally, NC605's encouraging preclinical results in chronic bone diseases and NC181's robust efficacy in Alzheimer's disease highlight the diversification of the company's portfolio, with ongoing patient enrollment signaling positive safety trends. The absence of standard of care in certain cancers and the potential for LNCB74 to significantly improve outcomes in challenging therapeutic areas enhances the overall value proposition for NextCure's stock moving forward.

Bears say

NextCure Inc's outlook is negatively impacted by the recent discontinuation of Pfizer's B7-H4 ADC program, SGN-B7H4V, which raises concerns about the viability of NextCure's own B7-H4-targeting therapy, LNCB74. Additionally, the company's operating expenses in the fourth quarter of 2024 exceeded expectations, contributing to a reduction in projected valuation from $4 to $3. These factors, coupled with the inherent risks of developing clinical-stage biopharmaceuticals, contribute to a cautious perspective on NextCure's financial future.

Nextcure (NXTC) has been analyzed by 11 analysts, with a consensus rating of Buy. 64% of analysts recommend a Strong Buy, 18% recommend Buy, 9% suggest Holding, 9% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nextcure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nextcure (NXTC) Forecast

Analysts have given Nextcure (NXTC) a Buy based on their latest research and market trends.

According to 11 analysts, Nextcure (NXTC) has a Buy consensus rating as of Jul 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.27, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.27, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nextcure (NXTC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.